Drug updated on 9/4/2024
| Dosage Form | Injection (intravenous; 1 g of sulbactam for injection [1 clear single-dose vial] and 0.5 g of durlobactam for injection [2 amber single-dose vials]) |
| Drug Class | Beta lactamase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
Latest News
Summary
- Xacduro (sulbactam and durlobactam) is indicated for patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- SUL-DUR demonstrated in vitro effectiveness by reverting sulbactam-resistant Acinetobacter baumannii isolates, including carbapenem-resistant strains, to a susceptible state, indicating enhanced activity of sulbactam when combined with durlobactam.
- The review did not provide comparative effectiveness data for SUL-DUR against other drugs or specify differences in effectiveness among different population types or subgroups.
- There is no safety information available in the reviewed studies.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Xacduro (sulbactam and durlobactam) Prescribing Information. | 2023 | Entasis Therapeutics Ltd., an affiliate of Innoviva Specialty Therapeutics, Waltham, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Sulbactam-durlobactam, a novel drug for the treatment of multidrug-resistant acinetobacter baumannii infections - a systematic review. | 2024 | Infectious Disorders Drug Targets |